The launch of this new collaboration builds on Aspect’s existing partnership with JSR Corporation

March 30, 2021
Aspect Biosystems

VANCOUVER, British Columbia – March 30, 2021 – Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the … Continue reading The launch of this new collaboration builds on Aspect’s existing partnership with JSR Corporation

Canadian healthcare leaders contribute to talent influx

March 29, 2021
BioTalent Canada

OTTAWA, March 29, 2021 – BioTalent Canada today announced the successful results of the expansion of the Student Work Placement Program (SWPP) to include the Canadian healthcare industry. The program’s expansion was in response to the needs of the healthcare industry, and an increased demand for talent caused by the COVID-19 pandemic.  Canada’s youth was one of the … Continue reading Canadian healthcare leaders contribute to talent influx

Doctors of BC 2020 Awards: Honouring BC’s outstanding doctors

March 25, 2021
Thrive Health

Each year, we acknowledge the outstanding contributions to the profession, to patients, and to the health care system itself by doctors across the province with our Doctors of BC Awards. Last year, BC doctors continued to innovate, collaborate, and adapt in unprecedented ways. From developing the patient centered COVID-19 Support App and Self-Assessment tool within … Continue reading Doctors of BC 2020 Awards: Honouring BC’s outstanding doctors

SignalChem Enters a Clinical Trial Collaboration with Merck to Evaluate the Effect of SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

March 23, 2021
SignalChem Lifesciences Corp.

VANCOUVER, BRITISH COLUMBIA – March 23, 2021. SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, announces a collaboration with Merck, known as MSD outside of the United States and Canada, through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, … Continue reading SignalChem Enters a Clinical Trial Collaboration with Merck to Evaluate the Effect of SLC-391 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer

iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.

March 22, 2021
iCo Therapeutics

Vancouver, British Columbia–(Newsfile Corp. – March 22, 2021) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo”) and Satellos Bioscience Inc. (“Satellos”), a private Canadian corporation, together are pleased to announce the execution of a definitive agreement, dated March 21, 2021 (the “Arrangement Agreement”), providing for the business combination of iCo and Satellos by way of … Continue reading iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.

A new study by Novateur Ventures provides global analysis of COVID-19 vaccines

March 18, 2021
Novateur Ventures

March 18, 2021 – A new study by Novateur Ventures provides a comparative analysis of twelve COVID-19 Vaccines that had initiated or announced the Phase III clinical trial stage by early November 2020. The study highlights the early successes, as well as the hurdles and barriers yet to be overcome for ending the global COVID-19 … Continue reading A new study by Novateur Ventures provides global analysis of COVID-19 vaccines

Western Economic Diversification Canada Accepting Expressions of Interest for Business Scale-up and Productivity Program

March 17, 2021
Western Economic Diversification Canada

March 17, 2021 – Once a start-up company is on its feet and needs to develop to the next stage, what next? That’s where the Business Scale-up and Productivity (BSP) program comes in. BSP supports high-growth Western Canadian firms that are scaling up and producing innovative goods, services or technologies through interest-free repayable funding. In the … Continue reading Western Economic Diversification Canada Accepting Expressions of Interest for Business Scale-up and Productivity Program

Chinook Therapeutics Announces First Patient Enrolled In Pivotal Phase 3 Align Study Of Atrasentan For Patients With IgA Nephropathy

March 16, 2021
Chinook Therapeutics Inc.

VANCOUVER, British Columbia and SEATTLE, March 16, 2021 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the ALIGN Study, a pivotal phase 3 clinical trial evaluating the efficacy and safety of … Continue reading Chinook Therapeutics Announces First Patient Enrolled In Pivotal Phase 3 Align Study Of Atrasentan For Patients With IgA Nephropathy

iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2

March 16, 2021
iCo Therapeutics

March 15, 2021, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in vivo efficacy of iCo’s novel oral amphotericin B asset (“iCo-019”) against SARS-CoV-2, the causative agent … Continue reading iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2